Cardinal Health, Inc.
https://www.cardinalhealth.com/en.html
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cardinal Health, Inc.
Dry Eye Crossover Study Could Allow Aldeyra A Quick Response To US FDA’s CRL For Reproxalap
Aldeyra’s bid to rely on a single Phase III trial after an initial one failed is rejected by FDA, but firm already has a special protocol assessment under review for a trial that could provide the symptom data it says agency needs to approve the RASP modulator in dry eye.
Aldeyra Plans Quick Response To FDA’s CRL For Reproxalap
Aldeyra already has a special protocol assessment under review at the FDA for a trial to provide the symptom data the agency said is needed for approval of the RASP modulator in dry eye disease.
Deal Watch: Graphite Exits Via Reverse Merger With Presbyopia Specialist LENZ
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
Durect Eyes Phase III In Alcoholic Hepatitis Despite Phase IIb Miss
Durect thinks its epigenetic modulator shows promise with data showing reduction in 90-day mortality despite missing the primary endpoint of mortality and liver transplant rate.
Company Information
- Industry
- Contract Research, Toxicology Testing-CRO
- Distributors
- Medical Devices
- Services
-
Services
- Home Infusion
- Hospitals, Nursing Homes, Institutions
- Pharmacy Services, PBMs
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
- Other Names / Subsidiaries
-
- AccessClosure
- Allegiance Healthcare Corporation
- Cordis Corporation
- Innovative Therapies, naviHealth
- OutcomesMTM
- The Harvard Drug Group
- VIASYS Healthcare
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice